Stock 603087 GAN & LEE PHARMACEUTICALS.
Add to a list
To use this feature you must be a member
Log inSign up

Financials Gan & Lee Pharmaceuticals.

Equities

603087

CNE100003ZH1

Pharmaceuticals

End-of-day quote Shanghai S.E.
Other stock markets
 06:00:00 2024-05-08 pm EDT 		5-day change 1st Jan Change
50.41 CNY +0.16% Intraday chart for Gan & Lee Pharmaceuticals. +0.74% -4.25%
Apr. 24 Gan & Lee Pharmaceuticals. Reports Earnings Results for the First Quarter Ended March 31, 2024 CI
Apr. 24 Gan & Lee Pharmaceuticals. Reports Earnings Results for the Full Year Ended December 31, 2023 CI

Valuation

Fiscal Period: December 2020 2021 2022 2023 2024 2025 2026
Capitalization 1 74,247 39,499 18,429 31,066 29,744 - -
Enterprise Value (EV) 1 74,247 39,499 18,429 28,627 27,464 26,652 25,614
P/E ratio 57.2 x 27.2 x -41.8 x 87.8 x 42.6 x 25.4 x 18.8 x
Yield - - - 0.38% 0.32% 0.4% 0.47%
Capitalization / Revenue 22.1 x 10.9 x - 11.9 x 8.16 x 6.48 x 5.27 x
EV / Revenue 22.1 x 10.9 x - 11 x 7.53 x 5.81 x 4.54 x
EV / EBITDA - - - 53.2 x 28.3 x 17.6 x 13.3 x
EV / FCF - - - - - - -
FCF Yield - - - - - - -
Price to Book 8.31 x 3.88 x - 2.91 x 2.58 x 2.35 x 2.09 x
Nbr of stocks (in thousands) 561,540 561,540 565,653 590,049 590,049 - -
Reference price 2 132.2 70.34 32.58 52.65 50.41 50.41 50.41
Announcement Date 4/14/21 4/27/22 3/30/23 4/24/24 - - -
1CNY in Million2CNY
Estimates

Income Statement Evolution (Annual data)

Fiscal Period: December 2019 2020 2021 2022 2023 2024 2025 2026
Net sales 1 2,895 3,362 3,612 - 2,608 3,647 4,588 5,644
EBITDA 1 - - - - 537.8 969.5 1,513 1,932
EBIT 1 - 1,453 1,699 - 315.3 759 1,277 1,734
Operating Margin - 43.22% 47.03% - 12.09% 20.81% 27.83% 30.72%
Earnings before Tax (EBT) 1 - 1,445 1,696 - 306.1 751.3 1,269 1,726
Net income 1 - 1,231 1,453 -439.5 340.1 703.3 1,178 1,590
Net margin - 36.61% 40.22% - 13.04% 19.29% 25.68% 28.18%
EPS 2 2.307 2.310 2.590 -0.7800 0.6000 1.182 1.982 2.675
Free Cash Flow - - - - - - - -
FCF margin - - - - - - - -
FCF Conversion (EBITDA) - - - - - - - -
FCF Conversion (Net income) - - - - - - - -
Dividend per Share 2 - - - - 0.2000 0.1600 0.2000 0.2350
Announcement Date 6/7/20 4/14/21 4/27/22 3/30/23 4/24/24 - - -
1CNY in Million2CNY
Estimates

Income Statement Evolution (Quarterly data)

Fiscal Period: December 2023 Q3 2023 Q4 2024 Q1 2024 Q2 2024 Q3 2024 Q4 2025 Q1
Net sales 1 - 702.4 560.3 792.4 1,049 1,468 677
EBITDA - - - - - - -
EBIT - -1.928 113.1 - - - -
Operating Margin - -0.27% 20.19% - - - -
Earnings before Tax (EBT) - - - - - - -
Net income 132.3 - - - - - -
Net margin - - - - - - -
EPS 2 0.2300 0.1300 0.1600 0.2200 0.3300 0.5200 0.3200
Dividend per Share - - - - - - -
Announcement Date 10/30/23 4/24/24 4/24/24 - - - -
1CNY in Million2CNY
Estimates

Balance Sheet Analysis

Fiscal Period: December 2019 2020 2021 2022 2023 2024 2025 2026
Net Debt 1 - - - - - - - -
Net Cash position 1 - - - - 2,439 2,281 3,092 4,130
Leverage (Debt/EBITDA) - - - - - - - -
Free Cash Flow - - - - - - - -
ROE (net income / shareholders' equity) - 17% 15.2% - 3.44% 5.98% 9.17% 11.1%
ROA (Net income/ Total Assets) - - - - - 5.34% 8.38% 10%
Assets 1 - - - - - 13,171 14,068 15,854
Book Value Per Share 2 - 15.90 18.10 - 18.10 19.60 21.40 24.10
Cash Flow per Share 2 - 2.210 1.920 - 0.1800 1.670 2.020 2.590
Capex 1 - - - - 553 719 267 350
Capex / Sales - - - - 21.19% 19.7% 5.82% 6.2%
Announcement Date 6/7/20 4/14/21 4/27/22 3/30/23 4/24/24 - - -
1CNY in Million2CNY
Estimates

EPS & Dividend

Year-on-year evolution of the PER

Year-on-year evolution of the Yield

Change in Enterprise Value/EBITDA

Ratings for Gan & Lee Pharmaceuticals.

Trading Rating
Investor Rating
ESG Refinitiv
C+
More Ratings

Analysts' Consensus

Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
4
Last Close Price
50.41 CNY
Average target price
62.5 CNY
Spread / Average Target
+23.98%
Consensus

EPS Revisions

Estimates Revisions

Quarterly earnings - Rate of surprise

Company calendar

Sector Biopharmaceuticals

1st Jan change Capi.
GAN & LEE PHARMACEUTICALS. Stock Gan & Lee Pharmaceuticals.
-4.25% 4.12B
CSL LIMITED Stock CSL Limited
-2.61% 88.47B
SAMSUNG BIOLOGICS CO.,LTD. Stock Samsung Biologics Co.,Ltd.
+2.76% 40.71B
BIOGEN INC. Stock Biogen Inc.
-13.92% 32.43B
UCB Stock UCB
+51.65% 24.28B
BIOMARIN PHARMACEUTICAL INC. Stock BioMarin Pharmaceutical Inc.
-15.25% 15.52B
CHONGQING ZHIFEI BIOLOGICAL PRODUCTS CO., LTD. Stock Chongqing Zhifei Biological Products Co., Ltd.
-39.93% 12.17B
BEIJING WANTAI BIOLOGICAL PHARMACY ENTERPRISE CO., LTD. Stock Beijing Wantai Biological Pharmacy Enterprise Co., Ltd.
-9.08% 12B
INCYTE CORPORATION Stock Incyte Corporation
-14.80% 12.01B
SWEDISH ORPHAN BIOVITRUM AB Stock Swedish Orphan Biovitrum AB
+5.99% 8.87B
Biopharmaceuticals
  1. Stock Market
  2. Equities
  3. 603087 Stock
  4. Financials Gan & Lee Pharmaceuticals.
-40% Limited Time Offer: Our subscriptions help you unlock hidden opportunities.
SIGN UP NOW